Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study - PubMed (original) (raw)
Clinical Trial
. 2008 Dec;143(5):707-15.
doi: 10.1111/j.1365-2141.2008.07294.x. Epub 2008 Oct 17.
Christoph Walz, Philipp Erben, Helena Popp, Annette Schmitt-Graeff, Claudia Haferlach, Alice Fabarius, Susanne Schnittger, David Grimwade, Nicholas C P Cross, Rüdiger Hehlmann, Andreas Hochhaus, Andreas Reiter
Affiliations
- PMID: 18950453
- DOI: 10.1111/j.1365-2141.2008.07294.x
Free article
Clinical Trial
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
Georgia Metzgeroth et al. Br J Haematol. 2008 Dec.
Free article
Abstract
This study evaluated the efficacy and safety of imatinib in chronic eosinophilic leukaemia (CEL, n = 23) and hypereosinophilic syndrome (HES, n = 13). In CEL with FIP1L1-PDGFRA (n = 16) or various PDGFRB fusion genes (n = 5), complete haematological remission (CHR) was achieved in 95% (20/21) after 3 months. Complete molecular remission (CMR) was seen in 75% (12/16) of cases with FIP1L1-PDGFRA positive CEL by 6 months, and in 87% (13/15) after 12 months. CMR was achieved in three of five PDGFRB fusion positive patients after 3, 9 and 18 months respectively. All patients are currently on imatinib (100 mg; n = 13, 400 mg; n = 8) and no molecular relapse has yet been observed (median 26.7 months; range, 6.9-39.9). Imatinib was less effective in HES and CEL without known molecular aberration (n = 15); CHR was observed in 40% (6/15) of patients, two patients relapsed after 4.8 and 24.5 months. Three patients died due to imatinib-resistant progressive CEL (n = 2) or myocardial infarction (n = 1) unrelated to study treatment. Overall, imatinib was well tolerated with a low incidence of grade III/IV toxicities. These data confirmed the long-term efficacy of imatinib for PDGFR-rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib.
Comment in
- Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
Helbig G, Moskwa A, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Zdziarska B, Brzeźniakiewicz K, Pogrzeba J, Krzemień S. Helbig G, et al. Br J Haematol. 2009 Apr;145(1):132-4. doi: 10.1111/j.1365-2141.2008.07546.x. Epub 2008 Dec 20. Br J Haematol. 2009. PMID: 19120352 No abstract available.
Similar articles
- A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. Helbig G, et al. Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26. Br J Haematol. 2008. PMID: 18307562 Clinical Trial. - Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Seferyńska I, Hałasz M, Woszczyk D, Markiewicz M, Krzemień S. Helbig G, et al. Hematol Oncol. 2010 Jun;28(2):93-7. doi: 10.1002/hon.919. Hematol Oncol. 2010. PMID: 19728396 - The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C. La Starza R, et al. Haematologica. 2005 May;90(5):596-601. Haematologica. 2005. PMID: 15921374 - FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J. Cools J. Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16089297 Review. - The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. Gotlib J, et al. Blood. 2004 Apr 15;103(8):2879-91. doi: 10.1182/blood-2003-06-1824. Epub 2003 Nov 20. Blood. 2004. PMID: 15070659 Review.
Cited by
- Epidemiology and prognostic nomogram for chronic eosinophilic leukemia: a population-based study using the SEER database.
Wang J, Lin M, Wang F. Wang J, et al. Sci Rep. 2024 Feb 26;14(1):4594. doi: 10.1038/s41598-024-55432-8. Sci Rep. 2024. PMID: 38409531 Free PMC article. - False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.
Pongdee T, Berry A, Wetzler L, Sun X, Thumm L, Yoon P, Kuang FL, Makiya M, Constantine G, Khoury P, Rheinbay E, Lane AA, Maric I, Klion AD. Pongdee T, et al. Acta Haematol. 2023;146(4):316-321. doi: 10.1159/000528046. Epub 2023 Jun 7. Acta Haematol. 2023. PMID: 37285821 Free PMC article. - Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas.
Helbig D, Klein S. Helbig D, et al. Front Oncol. 2022 Nov 17;12:975342. doi: 10.3389/fonc.2022.975342. eCollection 2022. Front Oncol. 2022. PMID: 36465341 Free PMC article. Review. - Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Valent P, et al. Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19. Allergy. 2023. PMID: 36207764 Free PMC article. Review. - Living without eosinophils: evidence from mouse and man.
Jackson DJ, Pavord ID. Jackson DJ, et al. Eur Respir J. 2023 Jan 12;61(1):2201217. doi: 10.1183/13993003.01217-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 35953100 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous